To explore the potential mechanism underlying the enhanced response of HBV+ non-liver cancer patients to anti-PD-1 therapy, we performed scRNA-seq on PBMCs and compared the features of each cell subset pre- and post-therapy in the 3 ESCC patients. Here, PDCD1 is linked to liver cancer.